Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
24
TNDM Quote, Financials, Valuation and Earnings
Last price:
$18.63
Seasonality move
:
20.79%
Day range:
$18.08 - $19.10
52-week range:
$9.98 - $29.65
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.22x
P/B ratio:
8.12x
Volume:
1M
Avg. volume:
2.8M
1-year change:
-1.48%
Market cap:
$1.3B
Revenue:
$1B
EPS (TTM):
-$3.07
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TNDM
Tandem Diabetes Care, Inc.
|
$240.6M | -$0.44 | 2.62% | -77.49% | $30.76 |
|
ABT
Abbott Laboratories
|
$11B | $1.15 | 6.19% | 54.77% | $132.28 |
|
GMED
Globus Medical, Inc.
|
$740.3M | $0.92 | 23.77% | 70.28% | $110.08 |
|
IRTC
iRhythm Holdings, Inc.
|
$194M | -$0.64 | 22.27% | -33.95% | $211.43 |
|
ISRG
Intuitive Surgical, Inc.
|
$2.6B | $2.13 | 16.31% | 10.98% | $605.08 |
|
PODD
Insulet Corp.
|
$729.9M | $1.20 | 28.28% | 138.1% | $351.43 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TNDM
Tandem Diabetes Care, Inc.
|
$18.61 | $30.76 | $1.3B | -- | $0.00 | 0% | 1.22x |
|
ABT
Abbott Laboratories
|
$102.87 | $132.28 | $179.6B | 27.81x | $0.63 | 2.32% | 4.08x |
|
GMED
Globus Medical, Inc.
|
$87.92 | $110.08 | $11.9B | 22.39x | $0.00 | 0% | 4.11x |
|
IRTC
iRhythm Holdings, Inc.
|
$116.80 | $211.43 | $3.7B | -- | $0.00 | 0% | 4.99x |
|
ISRG
Intuitive Surgical, Inc.
|
$452.07 | $605.08 | $156.3B | 55.87x | $0.00 | 0% | 15.86x |
|
PODD
Insulet Corp.
|
$204.31 | $351.43 | $14.2B | 57.60x | $0.00 | 0% | 5.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TNDM
Tandem Diabetes Care, Inc.
|
74.33% | 1.046 | 29.94% | 1.92x |
|
ABT
Abbott Laboratories
|
21.33% | 0.736 | 6.98% | 1.05x |
|
GMED
Globus Medical, Inc.
|
2.55% | -0.963 | 1.01% | 2.55x |
|
IRTC
iRhythm Holdings, Inc.
|
82.72% | 3.201 | 12.76% | 4.44x |
|
ISRG
Intuitive Surgical, Inc.
|
0.95% | 0.639 | 0.08% | 3.73x |
|
PODD
Insulet Corp.
|
39.8% | 2.432 | 5.01% | 1.82x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TNDM
Tandem Diabetes Care, Inc.
|
$167.5M | $8.3M | -32.45% | -121.88% | 2.86% | $3.1M |
|
ABT
Abbott Laboratories
|
$6.1B | $2.4B | 10.13% | 12.91% | 20.68% | $2.6B |
|
GMED
Globus Medical, Inc.
|
$536M | $181.6M | 11.94% | 12.49% | 21.98% | $202.3M |
|
IRTC
iRhythm Holdings, Inc.
|
$148.1M | $8.8M | -5.27% | -40.07% | 4.2% | $14.5M |
|
ISRG
Intuitive Surgical, Inc.
|
$1.9B | $864.3M | 16.53% | 16.59% | 30.16% | $730M |
|
PODD
Insulet Corp.
|
$570.3M | $146.3M | 9.17% | 17.89% | 18.67% | $33.9M |
Tandem Diabetes Care, Inc. vs. Competitors
-
Which has Higher Returns TNDM or ABT?
Abbott Laboratories has a net margin of -0.2% compared to Tandem Diabetes Care, Inc.'s net margin of 15.71%. Tandem Diabetes Care, Inc.'s return on equity of -121.88% beat Abbott Laboratories's return on equity of 12.91%.
Company Gross Margin Earnings Per Share Invested Capital TNDMTandem Diabetes Care, Inc.57.67% -$0.01 $604.5M ABTAbbott Laboratories53.5% $1.03 $66.9B -
What do Analysts Say About TNDM or ABT?
Tandem Diabetes Care, Inc. has a consensus price target of $30.76, signalling upside risk potential of 65.3%. On the other hand Abbott Laboratories has an analysts' consensus of $132.28 which suggests that it could grow by 28.59%. Given that Tandem Diabetes Care, Inc. has higher upside potential than Abbott Laboratories, analysts believe Tandem Diabetes Care, Inc. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings TNDMTandem Diabetes Care, Inc.9 11 0 ABTAbbott Laboratories16 7 0 -
Is TNDM or ABT More Risky?
Tandem Diabetes Care, Inc. has a beta of 1.737, which suggesting that the stock is 73.689% more volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.251%.
-
Which is a Better Dividend Stock TNDM or ABT?
Tandem Diabetes Care, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 2.32% to investors and pays a quarterly dividend of $0.63 per share. Tandem Diabetes Care, Inc. pays -- of its earnings as a dividend. Abbott Laboratories pays out 64.54% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TNDM or ABT?
Tandem Diabetes Care, Inc. quarterly revenues are $290.4M, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. Tandem Diabetes Care, Inc.'s net income of -$589K is lower than Abbott Laboratories's net income of $1.8B. Notably, Tandem Diabetes Care, Inc.'s price-to-earnings ratio is -- while Abbott Laboratories's PE ratio is 27.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care, Inc. is 1.22x versus 4.08x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNDMTandem Diabetes Care, Inc.1.22x -- $290.4M -$589K ABTAbbott Laboratories4.08x 27.81x $11.5B $1.8B
-
Which has Higher Returns TNDM or GMED?
Globus Medical, Inc. has a net margin of -0.2% compared to Tandem Diabetes Care, Inc.'s net margin of 17.01%. Tandem Diabetes Care, Inc.'s return on equity of -121.88% beat Globus Medical, Inc.'s return on equity of 12.49%.
Company Gross Margin Earnings Per Share Invested Capital TNDMTandem Diabetes Care, Inc.57.67% -$0.01 $604.5M GMEDGlobus Medical, Inc.64.85% $1.03 $4.7B -
What do Analysts Say About TNDM or GMED?
Tandem Diabetes Care, Inc. has a consensus price target of $30.76, signalling upside risk potential of 65.3%. On the other hand Globus Medical, Inc. has an analysts' consensus of $110.08 which suggests that it could grow by 25.21%. Given that Tandem Diabetes Care, Inc. has higher upside potential than Globus Medical, Inc., analysts believe Tandem Diabetes Care, Inc. is more attractive than Globus Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TNDMTandem Diabetes Care, Inc.9 11 0 GMEDGlobus Medical, Inc.6 4 0 -
Is TNDM or GMED More Risky?
Tandem Diabetes Care, Inc. has a beta of 1.737, which suggesting that the stock is 73.689% more volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.089, suggesting its more volatile than the S&P 500 by 8.928%.
-
Which is a Better Dividend Stock TNDM or GMED?
Tandem Diabetes Care, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care, Inc. pays -- of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNDM or GMED?
Tandem Diabetes Care, Inc. quarterly revenues are $290.4M, which are smaller than Globus Medical, Inc. quarterly revenues of $826.4M. Tandem Diabetes Care, Inc.'s net income of -$589K is lower than Globus Medical, Inc.'s net income of $140.6M. Notably, Tandem Diabetes Care, Inc.'s price-to-earnings ratio is -- while Globus Medical, Inc.'s PE ratio is 22.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care, Inc. is 1.22x versus 4.11x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNDMTandem Diabetes Care, Inc.1.22x -- $290.4M -$589K GMEDGlobus Medical, Inc.4.11x 22.39x $826.4M $140.6M
-
Which has Higher Returns TNDM or IRTC?
iRhythm Holdings, Inc. has a net margin of -0.2% compared to Tandem Diabetes Care, Inc.'s net margin of 2.67%. Tandem Diabetes Care, Inc.'s return on equity of -121.88% beat iRhythm Holdings, Inc.'s return on equity of -40.07%.
Company Gross Margin Earnings Per Share Invested Capital TNDMTandem Diabetes Care, Inc.57.67% -$0.01 $604.5M IRTCiRhythm Holdings, Inc.70.88% $0.17 $883.9M -
What do Analysts Say About TNDM or IRTC?
Tandem Diabetes Care, Inc. has a consensus price target of $30.76, signalling upside risk potential of 65.3%. On the other hand iRhythm Holdings, Inc. has an analysts' consensus of $211.43 which suggests that it could grow by 81.02%. Given that iRhythm Holdings, Inc. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe iRhythm Holdings, Inc. is more attractive than Tandem Diabetes Care, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TNDMTandem Diabetes Care, Inc.9 11 0 IRTCiRhythm Holdings, Inc.12 1 0 -
Is TNDM or IRTC More Risky?
Tandem Diabetes Care, Inc. has a beta of 1.737, which suggesting that the stock is 73.689% more volatile than S&P 500. In comparison iRhythm Holdings, Inc. has a beta of 1.180, suggesting its more volatile than the S&P 500 by 17.985%.
-
Which is a Better Dividend Stock TNDM or IRTC?
Tandem Diabetes Care, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care, Inc. pays -- of its earnings as a dividend. iRhythm Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNDM or IRTC?
Tandem Diabetes Care, Inc. quarterly revenues are $290.4M, which are larger than iRhythm Holdings, Inc. quarterly revenues of $208.9M. Tandem Diabetes Care, Inc.'s net income of -$589K is lower than iRhythm Holdings, Inc.'s net income of $5.6M. Notably, Tandem Diabetes Care, Inc.'s price-to-earnings ratio is -- while iRhythm Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care, Inc. is 1.22x versus 4.99x for iRhythm Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNDMTandem Diabetes Care, Inc.1.22x -- $290.4M -$589K IRTCiRhythm Holdings, Inc.4.99x -- $208.9M $5.6M
-
Which has Higher Returns TNDM or ISRG?
Intuitive Surgical, Inc. has a net margin of -0.2% compared to Tandem Diabetes Care, Inc.'s net margin of 27.89%. Tandem Diabetes Care, Inc.'s return on equity of -121.88% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.
Company Gross Margin Earnings Per Share Invested Capital TNDMTandem Diabetes Care, Inc.57.67% -$0.01 $604.5M ISRGIntuitive Surgical, Inc.66.41% $2.21 $18.1B -
What do Analysts Say About TNDM or ISRG?
Tandem Diabetes Care, Inc. has a consensus price target of $30.76, signalling upside risk potential of 65.3%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $605.08 which suggests that it could grow by 33.85%. Given that Tandem Diabetes Care, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe Tandem Diabetes Care, Inc. is more attractive than Intuitive Surgical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TNDMTandem Diabetes Care, Inc.9 11 0 ISRGIntuitive Surgical, Inc.17 9 1 -
Is TNDM or ISRG More Risky?
Tandem Diabetes Care, Inc. has a beta of 1.737, which suggesting that the stock is 73.689% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.677, suggesting its more volatile than the S&P 500 by 67.7%.
-
Which is a Better Dividend Stock TNDM or ISRG?
Tandem Diabetes Care, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care, Inc. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNDM or ISRG?
Tandem Diabetes Care, Inc. quarterly revenues are $290.4M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Tandem Diabetes Care, Inc.'s net income of -$589K is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Tandem Diabetes Care, Inc.'s price-to-earnings ratio is -- while Intuitive Surgical, Inc.'s PE ratio is 55.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care, Inc. is 1.22x versus 15.86x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNDMTandem Diabetes Care, Inc.1.22x -- $290.4M -$589K ISRGIntuitive Surgical, Inc.15.86x 55.87x $2.9B $799.5M
-
Which has Higher Returns TNDM or PODD?
Insulet Corp. has a net margin of -0.2% compared to Tandem Diabetes Care, Inc.'s net margin of 12.96%. Tandem Diabetes Care, Inc.'s return on equity of -121.88% beat Insulet Corp.'s return on equity of 17.89%.
Company Gross Margin Earnings Per Share Invested Capital TNDMTandem Diabetes Care, Inc.57.67% -$0.01 $604.5M PODDInsulet Corp.72.76% $1.44 $2.5B -
What do Analysts Say About TNDM or PODD?
Tandem Diabetes Care, Inc. has a consensus price target of $30.76, signalling upside risk potential of 65.3%. On the other hand Insulet Corp. has an analysts' consensus of $351.43 which suggests that it could grow by 72.01%. Given that Insulet Corp. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Insulet Corp. is more attractive than Tandem Diabetes Care, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TNDMTandem Diabetes Care, Inc.9 11 0 PODDInsulet Corp.17 1 0 -
Is TNDM or PODD More Risky?
Tandem Diabetes Care, Inc. has a beta of 1.737, which suggesting that the stock is 73.689% more volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.470, suggesting its more volatile than the S&P 500 by 47.012%.
-
Which is a Better Dividend Stock TNDM or PODD?
Tandem Diabetes Care, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care, Inc. pays -- of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNDM or PODD?
Tandem Diabetes Care, Inc. quarterly revenues are $290.4M, which are smaller than Insulet Corp. quarterly revenues of $783.8M. Tandem Diabetes Care, Inc.'s net income of -$589K is lower than Insulet Corp.'s net income of $101.6M. Notably, Tandem Diabetes Care, Inc.'s price-to-earnings ratio is -- while Insulet Corp.'s PE ratio is 57.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care, Inc. is 1.22x versus 5.33x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNDMTandem Diabetes Care, Inc.1.22x -- $290.4M -$589K PODDInsulet Corp.5.33x 57.60x $783.8M $101.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
